Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Rome, Italy.
EuroIntervention. 2022 Oct 7;18(8):e666-e676. doi: 10.4244/EIJ-D-21-00971.
Intracoronary provocation testing with acetylcholine (ACh) is crucial for the diagnosis of functional coronary alterations in patients with suspected myocardial ischaemia and non-obstructive coronary arteries.
Our intention was to assess the safety and predictive value for major adverse cardiovascular and cerebrovascular events (MACCE) in patients presenting with ischaemia with non-obstructive coronary arteries (INOCA) or with myocardial infarction with non-obstructive coronary arteries (MINOCA).
We prospectively enrolled consecutive INOCA or MINOCA patients undergoing intracoronary ACh provocation testing.
A total of 317 patients were enrolled: 174 (54.9%) with INOCA and 143 (45.1%) with MINOCA. Of these, 185 patients (58.4%) had a positive response to the ACh test. Complications during ACh provocative testing were all mild and transient and occurred in 29 (9.1%) patients, with no difference between patients with positive or negative responses to ACh testing, nor between INOCA and MINOCA patients. A history of paroxysmal atrial fibrillation, moderate/severe diastolic dysfunction and a higher QT dispersion at baseline electrocardiogram were independent predictors of complications. MACCE occurred in 30 patients (9.5%) during a median follow-up of 22 months. The incidence of MACCE was higher among patients with a positive ACh test (24 [13.0%] vs 6 [4.5%], p=0.017), and a positive ACh test was an independent predictor of MACCE.
ACh provocation testing is associated with a low risk of mild and transient complications, with a similar prevalence in both INOCA and MINOCA patients. Importantly, ACh provocation testing can help to identify patients at higher risk of future clinical events, suggesting a net clinical benefit derived from its use in this clinical setting.
在疑似心肌缺血和非阻塞性冠状动脉疾病患者中,冠状动脉内乙酰胆碱(ACh)激发试验对于功能性冠状动脉改变的诊断至关重要。
我们旨在评估在缺血性非阻塞性冠状动脉疾病(INOCA)或非阻塞性冠状动脉心肌梗死(MINOCA)患者中,进行冠状动脉内 ACh 激发试验的安全性和对主要不良心血管和脑血管事件(MACCE)的预测价值。
我们前瞻性纳入连续接受冠状动脉内 ACh 激发试验的 INOCA 或 MINOCA 患者。
共纳入 317 例患者:174 例(54.9%)为 INOCA,143 例(45.1%)为 MINOCA。其中 185 例(58.4%)患者对 ACh 试验有阳性反应。ACh 激发试验过程中的并发症均为轻度和一过性,发生在 29 例(9.1%)患者中,在 ACh 试验阳性或阴性反应的患者之间、INOCA 和 MINOCA 患者之间均无差异。阵发性心房颤动史、中重度舒张功能障碍和基线心电图 QT 离散度较高是并发症的独立预测因素。在中位随访 22 个月期间,30 例患者(9.5%)发生 MACCE。ACh 试验阳性的患者 MACCE 发生率更高(24 [13.0%] vs 6 [4.5%],p=0.017),ACh 试验阳性是 MACCE 的独立预测因素。
ACh 激发试验相关的轻度和一过性并发症风险较低,在 INOCA 和 MINOCA 患者中的发生率相似。重要的是,ACh 激发试验可帮助识别未来临床事件风险较高的患者,提示在这种临床情况下使用 ACh 激发试验具有净临床获益。